Kanya Rajangam, M.D., Ph.D.

Kanya Rajangam, M.D., Ph.D.

President, Head of Research and Development and Chief Medical OfficeratSenti Biosciences Holdings· In proxies 2022–2024

Pay in FY2024-27% from the year before · Senti Biosciences Holdings stock -46.8% the same year

Kanya Rajangam, M.D., Ph.D. was paid $627.7K in FY2024 (Dec), down 27%. Senti Biosciences Holdings stock fell 46.8% that year.

Pay$100 in the stock at the end of FY21 → $4
Pay is from the Summary Compensation Table of each Senti Biosciences Holdings proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Senti Biosciences HoldingsPublic company · 4 yr
    • President, Head of Research and Development and Chief Medical Officer2022 – Present · 4 yrStock in role -100%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?